Rachel Gilmour

I shall come to just that point in a minute. This sounds strange now, but I am going to say it: take obesity, for example. One in three people in the UK are currently classified as obese. Obesity is estimated to cost the NHS over £11.4 billion a year, with wider societal costs to the tune of £74 billion a year. Community pharmacies are ideally placed to provide wraparound support for those prescribed weight-loss medicines as part of an NHS-commissioned service, but they need the resources and the commissioning framework to do so. There is one aspect of this debate that receives insufficient attention, and I want to raise it briefly. The ongoing situation in the middle east has hit the pharmaceutical supply chain as much as any other sector. There were a record 219 price concessions announced for community pharmacies in May alone, with further negotiations still ongoing. The cost of medicines has risen sharply. I understand that some cancer drugs have reportedly seen elevenfold increases. Crucially, medicine shortages and record-high price concessions reflect an instability in the supply chain that is being intensified by geopolitical pressures. I put it to the Government that the growing medicine supply crisis poses serious risks to Britain’s preparedness and resilience.